Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.

Abstract

8035 Background: There remains a lack of prospective data studying ABVD or Stanford V in the modern era in advanced-stage elderly HL (≥60 years). METHODS We analyzed outcomes and tolerability of elderly pts with advanced-stage HL treated in E2496. Pts were randomizedto ABVD chemotherapy (CT) x 6-8cycles + radiotherapy (RT) for bulky disease or StanfordV… (More)

Topics

Cite this paper

@article{Evens2011EfficacyAT, title={Efficacy and tolerability of ABVD and Stanford V for elderly advanced-stage Hodgkin lymphoma (HL): Analysis from the phase III randomized U.S. Intergroup Trial E2496.}, author={Andrew M. Evens and Fashui Hong and L I Gordon and Richard I. Fisher and Nancy L. Bartlett and Joseph M. Connors and Henry Wagner and Mary Krystyna Gospodarowicz and Bruce D David Cheson and Ranjana Hira Advani and Brad S Kahl and Richard T. Hoppe and Sandra J. Horning}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2011}, volume={29 15_suppl}, pages={8035} }